Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 7
Submit an article Journal homepage
1,255
Views
2
CrossRef citations to date
0
Altmetric
Articles

Early versus late response to daratumumab-based triplet therapies in patients with multiple myeloma: a pooled analysis of trials POLLUX, CASTOR and MAIA

Jiasheng Wanga Department of Hematology and Oncology, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-3053-5439
ORCID Icon,
Raul Arroyo-Suarezb Department of Internal Medicine, MetroHealth Medical Center, Cleveland, OH, USA
,
Srilatha Dasarib Department of Internal Medicine, MetroHealth Medical Center, Cleveland, OH, USA
,
Kanithra Sekaranb Department of Internal Medicine, MetroHealth Medical Center, Cleveland, OH, USA
&
William Tsec Department of Hematology and Oncology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH, USACorrespondence[email protected]
Pages 1669-1677 | Received 29 Nov 2021, Accepted 23 Jan 2022, Published online: 10 Feb 2022

References

  • Panzer-Grumayer ER, Schneider M, Panzer S, et al. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. Blood. 2000;95(3):790–794.
  • Schaar CG, Kluin-Nelemans JC, Le Cessie S, et al. Early response to therapy and survival in multiple myeloma. Br J Haematol. 2004;125(2):162–166.
  • Harousseau JL, Palumbo A, Richardson PG, et al. Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. Blood. 2010;116(19):3743–3750.
  • Tandon N, Sidana S, Rajkumar SV, et al. Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma. Blood Adv. 2019;3(5):744–750.
  • Yan Y, Mao X, Liu J, et al. The impact of response kinetics for multiple myeloma in the era of novel agents. Blood Adv. 2019;3(19):2895–2904.
  • Mellors PW, Binder M, Buadi FK, et al. Time to Plateau as a predictor of survival in newly diagnosed multiple myeloma. Am J Hematol. 2018;93(7):889–894.
  • Garderet L, Laubach JP, Stoppa AM, et al. Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1. Leukemia. 2018;32(9):2032–2036.
  • Lonial S, Anderson KC. Association of response endpoints with survival outcomes in multiple myeloma. Leukemia. 2014;28(2):258–268.
  • Mateos MV, Cavo M, Blade J, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly. Lancet. 2020;395(10218):132–141. [doi].
  • Bahlis NJ, Dimopoulos MA, White DJ, et al. Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia. 2020;34(7):1875–1884.
  • Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(14):1319–1331.
  • Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8):754–766.
  • Facon T, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019;380(22):2104–2115. ‐
  • Belch A, Shelley W, Bergsagel D, et al. A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients. Br J Cancer. 1988;57(1):94–99.
  • Boccadoro M, Marmont F, Tribalto M, et al. Early responder myeloma: kinetic studies identify a patient subgroup characterized by very poor prognosis. J Clin Oncol. 1989;7(1):119–125.
  • Marmont F, Levis A, Falda M, et al. Lack of correlation between objective response and death rate in multiple myeloma patients treated with oral melphalan and prednisone. Ann Oncol. 1991;2(3):191–195.
  • Avet-Loiseau H, San-Miguel J, Casneuf T, et al. Evaluation of sustained minimal residual disease negativity with Daratumumab-Combination regimens in relapsed and/or refractory multiple myeloma: Analysis of POLLUX and CASTOR. J Clin Oncol. 2021;39(10):1139–1149.
  • Munshi NC, Avet-Loiseau H, Anderson KC, et al. A large Meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020;4(23):5988–5999.
  • Perrot A, Lauwers-Cances V, Cazaubiel T, et al. Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: long-term follow-up analysis of the IFM 2009 trial. Blood. 2020;136(Supplement 1):39–39.
  • Dimopoulos MA, Kastritis E, Christoulas D, et al. Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies. Leukemia. 2010;24(10):1769–1778.
  • Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33(9):2266–2275.
  • van Rhee F, Bolejack V, Hollmig K, et al. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood. 2007;110(3):827–832.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.